Optometrists in Olney, MD Accepting Medicare

6 Optometrists found. Showing 1 - 6

Dr. Jp Kim, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 18111 Town Center Dr, Olney, MD 20832 Phone: 301-570-1600    Fax: 301-839-1867

Ms. Jasleen K Bedi, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 18111 Town Center Dr, Olney, MD 20832 Phone: 301-570-1600    Fax: 301-839-1867

Myeyedr Optometrist Medicare: Medicare Enrolled Practice Location: 18111 Town Center Dr, Olney, MD 20832 Phone: 301-570-1600    Fax: 301-570-1602

Dr. Susan Chiu Brule, O.D. Optometrist Medicare: Medicare Enrolled Practice Location: 3423 Olney Laytonsville Rd Ste 2, Olney, MD 20832 Phone: 301-774-2434    Fax: 301-774-0312

Kimberly S Kepner, O.D. Optometrist Medicare: Not Enrolled in Medicare Practice Location: 3423 Olney Laytonsville Rd, Suite 2, Olney, MD 20832 Phone: 301-774-2434    Fax: 301-774-0312

Ms. Renu Elsa Mathew, O.D. Optometrist Medicare: Accepting Medicare Assignments Practice Location: 18111 Town Center Dr, Olney, MD 20832 Phone: 301-570-1600    Fax: 301-839-1867

News Archive

Accretive Health prices initial public offering at $12.00 per share

Accretive Health, Inc., a provider of end-to-end revenue cycle management services for U.S. healthcare providers today announced the initial public offering of 10,000,000 shares of its common stock at a price to the public of $12.00 per share. Of the 10,000,000 shares being offered to the public, 6,666,667 shares are being offered by Accretive Health and 3,333,333 shares are being offered by selling stockholders.

Having two attending surgeons is better and safer during complex spinal surgeries

Two heads are better than one, as the saying goes - and a new study by a duo at the University of California, San Francisco (UCSF) demonstrates how having two attending surgeons in the operating room during spinal surgeries can benefit patients in multiple ways.

Use Medicare to hold industry to cost and quality promises

On June 1, leaders of the health care industry reaffirmed their pledge to reform a health care system that is rife with inefficiencies, costs too much, and fails to deliver the quality of care Americans expect.

Presidio Pharmaceuticals completes Phase 1a clinical trial of PPI-461 in healthy subjects

Presidio Pharmaceuticals, Inc. announced today the successful completion of a Phase 1a clinical trial of PPI-461, its lead HCV NS5A inhibitor, in healthy subjects. This first-in-human trial evaluated four single doses of PPI-461, followed by a five-day, once-a-day treatment regimen with PPI-461 at the highest tested dose.

TB Alliance receives pledge of up to $40 million from USAID

The Global Alliance for TB Drug Development (TB Alliance), a not-for-profit, product development partnership leading the development of new and affordable tuberculosis (TB) drugs, announced today a new grant and pledge of up to $40 million over the next five years from the United States Agency for International Development (USAID).

Read more Medical News

› Verified 4 days ago